Market revenue in 2023 | USD 166.5 million |
Market revenue in 2030 | USD 299.8 million |
Growth rate | 8.8% (CAGR from 2023 to 2030) |
Largest segment | Small molecule |
Fastest growing segment | Large Molecule |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule, Large Molecule |
Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Small molecule was the largest segment with a revenue share of 63.66% in 2023. Horizon Databook has segmented the Japan in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
Japan’s in vivo CRO market is witnessing growth on the back of increasing harmonization between CROs and pharmaceutical & biotech companies, as well as the implementation of faster regulatory processes. The government is actively taking various initiatives to improve the country’s regulatory review performance and clinical trial infrastructure. These efforts are expected to boost the in vivo CRO market growth during the forecast period.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account